Transcript
A (0:01)
Live from NPR News. In Washington, I'm Jeanine Herbst. The White House says U.S. negotiators are planning to head to Islamabad, Pakistan, for talks this weekend with Iran. This after President Trump extended a ceasefire in the U S. Israeli war in Iran indefinitely. White House Press Secretary Caroline Levitt the
B (0:19)
president was flexible in granting an extension of the ceasefire throughout this time. The president has decided to dispatch special envoy Witkoff and Jared Kushner back to Islamabad. The Iranians want to talk. They want to talk in person.
A (0:34)
But Tehran says Foreign Minister Abbas Aradchi, who's already in Islamabad, is there for talks with Russia and Oman along with senior Pakistani officials. And a ministry spokesperson says on X tonight that there are no planned meetings between the US And Iran. The White House hasn't commented. Meanwhile, both Iran and the US Continue their blockade of the Strait of Hormuz, the critical waterway where some 20% of the world's oil travels through. The Trump administration has extended a waiver of the Jones act through the end of August. It's an attempt to help with domestic supplies of gas and other refined oil products. NPR's Camilla Dominosky reports. Waiving the act makes it easier to move fuel around, but it doesn't significantly affect prices.
C (1:19)
The Jones act requires goods shipped from one US Port to another to be sent on a US Built ship with a US Crew. The the requirement boosts the domestic shipbuilding industry but creates a headache for other industries. There just aren't very many ships that qualify. The initial 60 day waiver of the act was meant to help companies adapt to the global disruption in oil supplies caused by the Iran war. Experts say it does make it easier to ship fuels from U.S. refineries to U.S. customers. But the effect on gasoline prices for consumers is minimal. By some estimates, as little as a fraction fraction of a penny. Camila Domonosky, NPR News.
A (1:59)
The Food and Drug Administration is now speeding up its review of psychedelics for treating mental health issues and is giving priority status to several psychedelic drugs which companies have been studying for depression and PTSD. NPR's Will Stone has more.
D (2:15)
Three companies are submitting drug applications to the fda. Two are for psilocybin, the active ingredient in magic mushrooms, for treating depression. The third is for a drug that's similar to mdma, which has shown promise for pts. FDA is giving out special vouchers that are intended to expedite the agency's review of the drugs. It does not mean the drugs are FDA approved yet. This comes on the heels of an executive order from President Trump that directs federal health agencies to prioritize research on psychedelics. Scientific interest in these drugs for treating mental health has grown substantially in the last few years, though an effort to get MDMA approved for treating PTSD fell short in 2024. Will Stone, NPR News.
